a16z Bio + Health | LinkedIn (original) (raw)
Financial Services
Backing bold entrepreneurs who are engineering biology and reimagining healthcare.
About us
Backing bold entrepreneurs who are engineering biology and reimagining healthcare.
Industry
Financial Services
Company size
201-500 employees
Headquarters
The Cloud
Updates
-
18,612 followers
6d Edited
Who’s at #AHIPDigital?Julie Yoo, a16z general partner, is presenting today, September 24th, on Best in Class Digital Health Engagement Insights from Other Industries. She'll be in good company — 500 hundred forward-thinking healthcare leaders are coming together to dig deep into how new tech translates to more personalized care and better health outcomes. More here: https://lnkd.in/eMY5xdEj - How do you simplify Medicaid navigation for millions of Americans? The process is notoriously complex, varying by state and fraught with barriers like changing eligibility rules, confusing enrollment options, and language limitations. Nikita Singareddy, CEO of Fortuna Health, outlines a three-part approach in her conversation with a16z venture partner, William Shrank: 👉🏼 Eligibility awareness: Helping households understand Medicaid eligibility, which vary based on income, immigration status, and even medical conditions. 👉🏼 Accurate enrollment: Ensuring the right information is submitted across different application methods (online, paper, in-person). 👉🏼 Renewal support: Guiding users through the renewal process to avoid denial or lapses in coverage. Listen on Raising Health: https://lnkd.in/gf_vNcyy
- “GC Therapeutics is flipping the entire iPSC differentiation paradigm on its head. Rather than manually iterating through a limited set of differentiation protocols, the Human TFome technology platform instead deploys large-scale combinatorial screening to discover new hypotheses and better methods that are as-yet unknown to even the best biologists.” - Vineeta Agarwala, MD PhD, a16z general partner. Read the full investment thesis from Vineeta here: https://lnkd.in/gG8UaJdC
- For many hard-to-treat diseases, delivering functional cells back to patients could offer enormous clinical benefit. But scaling cellular medicines is not an easy task. We believe GC Therapeutics’ innovative TFome™ platform will overcome this barrier by streamlining the differentiation and development of off-the-shelf iPSC-derived cell therapies, enabling rapid production with improved potency, efficiency, and scalability. Welcome GC Therapeutics to the a16z Bio + Health portfolio! None of the above should be taken as investment advice or an advertisement for investment services; please see https://lnkd.in/gjmYWkHi for more information.
Exciting news! GC Therapeutics is officially launched with a mission to revolutionize #celltherapy using the world’s first “plug-and-play” iPSC cellular programming platform, TFome™, through the integration of the latest advancements in synthetic #biology, #geneediting, cell engineering and #machinelearning. Developed by a world-class team of scientists and operators and originated based on the foundational work from the lab of Professor George Church, Ph.D at Harvard University, GCTx aims to streamline development and accelerate a pipeline of potential best-in-class cell therapies across diverse therapeutic areas. To learn more, read our full release below and visit us at https://www.gc-tx.com.https://lnkd.in/edA2R3BC - As more people handle out-of-pocket healthcare expenses, there’s a growing need for platforms that simplify the experience for these "micro payors." Health insurance marketplaces like ACA and Medicare Advantage already put spending control in consumers' hands. But more seamless tools are needed—like integrating payment systems, tax law compliance, and user-friendly interfaces to make insurance shopping easier. Plus, cash-pay services, healthcare-specific financing like BNPL, and innovative funding tools (like ICHRA or directed spend cards) are helping consumers manage and reduce healthcare costs. The rise of consumer-driven healthcare spending signals a future where free market dynamics may foster more competition and efficiency in the system. Read the full analysis from Julie Yoo: https://lnkd.in/gr5Zhqay
- Partnering with Medicaid can unlock opportunities, but it requires an understanding of its complexities. Medicaid is growing rapidly, covering about a third of California's population and funding nearly half of all births. However, access issues persist due to bureaucracy, eligibility hurdles, and underfunding. We've put together a 3-part series - Medicaid Matters - focused on demystifying Medicaid for entrepreneurs. Check out episode one with Mark Smith, Clinical Professor of Medicine at University of California, San Francisco, in conversation with a16z venture partner, William Shrank. Listen on Raising Health: https://lnkd.in/efyDzmr2
- While advanced algorithms are valuable, the true differentiator is the ability to generate and control clean, relevant data. Unique data enables companies to build more accurate models and innovate solutions that are difficult for competitors to replicate. Recently, Kim Branson, SVP Artificial Intelligence & Machine Learning at GSK, sat down with Vijay Pande, PhD, a16z general partner, to discuss how AI is impacting our industry and what comes next. Watch the full conversation here: https://lnkd.in/dE6hXZCX
- Congratulations to Genesis Therapeutics! None of the above should be taken as investment advice or an advertisement for investment services; please see https://lnkd.in/gjmYWkHi for more information.
10,159 followers
2w Edited
We’re thrilled to announce our collaboration with Gilead! Together, we’re combining forces to accelerate groundbreaking discoveries and push the boundaries of what’s possible in drug development. This partnership highlights the power of our AI platform, GEMS, and our shared commitment to creating innovative and breakthrough medicines for patients with high unmet medical need. Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies | Business Wirehttps://lnkd.in/g6d_gFBA - Vijay Pande, PhD, a16z general partner, recently joined the AI x a16z podcast to explore the intersection of AI, biotechnology, and healthcare, highlighting the immense potential and challenges of these rapidly evolving fields. Vijay shares his thoughts on: 👉🏼 How we can transform care quality, access, and reduce costs by leveraging AI 👉🏼 How early AI healthcare companies have an opportunity to build comprehensive full stack solutions to innovate our health 👉🏼 How companies can merge computational and drug design expertise to build successful cross functional teams. Listen on Raising Health: https://lnkd.in/det5FJ2E
- The intricate nature of developing and administering cell therapies makes them expensive and logistically challenging. As we look to the future, simplifying the process to reduce costs will be critical in making these life-saving treatments more widely available. Recently, Jorge Conde, a16z general partner, and Ginger Liau, welcomed Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania on the Raising Health podcast to discuss the next generation of cell and gene therapies. Listen here: https://lnkd.in/eSHGv9kx